Genmab starts Phase II psoriasis study

Genmab (CSE:GEN; NMarkt:GE9D) began placebo-controlled Phase II testing of its HuMax-CD4 human antibody against the CD4 receptor on T cells to treat severe psoriasis. In December, the company began Ph...